Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human breast cancer samples that were treated with tamoxifen identifier a 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

ABSTRACT: Classification of tamixifen-treated breast cancer patients into high and low risk groups using the 76-gene signature Experiment Overall Design: 136 breast cancer samples that were treated with tamoxifen were classified using the 76-gene signature

ORGANISM(S): Homo sapiens

SUBMITTER: Zhang Y

PROVIDER: S-ECPF-GEOD-12093 | biostudies-other | 2009 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy

Project description:Classification of tamixifen-treated breast cancer patients into high and low risk groups using the 76-gene signature

2008-10-07 | GSE12093 | GEO

Transcription profiling of human breast cancer samples that were treated with tamoxifen identifier a 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Project description:Classification of tamixifen-treated breast cancer patients into high and low risk groups using the 76-gene signature Experiment Overall Design: 136 breast cancer samples that were treated with tamoxifen were classified using the 76-gene signature

2008-10-26 | E-GEOD-12093 | biostudies-arrayexpress

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

Project description: Not available

| S-EPMC5668340 | biostudies-literature

Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.

Project description: Not available

| S-EPMC4792578 | biostudies-literature

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

Project description: Not available

| S-EPMC3695326 | biostudies-literature

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant Tamoxifen mono-therapy: a DBCG study

Project description:Purpose: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer patients treated with adjuvant Tamoxifen with regards to probability of recurrence. Experimental design: Global miRNA analysis was performed on 152 ER+ primary tumors from high-risk breast cancer patients with an initial discovery set of 52 patients, followed by 2 independent test sets (N=60 and N=40). All patients had received adjuvant Tamoxifen as mono-therapy (median clinical follow-up: 4.6 years) and half had developed distant recurrence (median time-to-recurrence: 3.5 years). MiRNA expression was examined by unsupervised hierarchical clustering and supervised analysis, including clinical parameters as co-variables.

2012-04-19 | GSE37405 | GEO

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.

Project description: Not available

| S-EPMC6927322 | biostudies-literature

Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Project description: Not available

| S-EPMC4943575 | biostudies-literature

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study.

Project description: Not available

| S-EPMC3356496 | biostudies-literature

Risk-benefit profiles of women using tamoxifen for chemoprevention.

Project description: Not available